diethylcarbamazine has been researched along with Proteinuria in 6 studies
Diethylcarbamazine: An anthelmintic used primarily as the citrate in the treatment of filariasis, particularly infestations with Wucheria bancrofti or Loa loa.
Proteinuria: The presence of proteins in the urine, an indicator of KIDNEY DISEASES.
| Excerpt | Relevance | Reference |
|---|---|---|
| "In the last ten years ivermectin appeared an efficient and safe alternative to diethylcarbamazine which is known to induce severe adverse reactions in loiasis, including encephalitis." | 3.69 | [Secondary effects of the treatment of hypermicrofilaremic loiasis using ivermectin]. ( Boussinesq, M; Chippaux, JP; Ducorps, M; Gardon, J; Gardon-Wendel, N; Ndong, W; Ranque, S; Schneider, D, 1995) |
| Timeframe | Studies, this research(%) | All Research% |
|---|---|---|
| pre-1990 | 3 (50.00) | 18.7374 |
| 1990's | 3 (50.00) | 18.2507 |
| 2000's | 0 (0.00) | 29.6817 |
| 2010's | 0 (0.00) | 24.3611 |
| 2020's | 0 (0.00) | 2.80 |
| Authors | Studies |
|---|---|
| Greene, BM | 2 |
| Taylor, HR | 2 |
| Humphrey, RL | 2 |
| Ngu, JL | 1 |
| Mate, A | 1 |
| Leke, R | 1 |
| Titanji, V | 1 |
| Brown, EJ | 1 |
| Lawley, TJ | 1 |
| Ducorps, M | 1 |
| Gardon-Wendel, N | 1 |
| Ranque, S | 1 |
| Ndong, W | 1 |
| Boussinesq, M | 1 |
| Gardon, J | 1 |
| Schneider, D | 1 |
| Chippaux, JP | 1 |
| Langhammer, J | 1 |
| Birk, HW | 1 |
| Zahner, H | 1 |
| Dreyer, G | 1 |
| Ottesen, EA | 1 |
| Galdino, E | 1 |
| Andrade, L | 1 |
| Rocha, A | 1 |
| Medeiros, Z | 1 |
| Moura, I | 1 |
| Casimiro, I | 1 |
| Beliz, F | 1 |
| Coutinho, A | 1 |
| Trial | Phase | Enrollment | Study Type | Start Date | Status | ||
|---|---|---|---|---|---|---|---|
| Safety and Efficacy of Combination Therapy With Ivermectin, Diethylcarbamazine, and Albendazole (IDA) for Individuals With Onchocerciasis[NCT04188301] | Phase 2 | 154 participants (Actual) | Interventional | 2019-12-06 | Completed | ||
| Safety and Efficacy of Novel Combination Regimens for Treatment of Onchocerciasis[NCT06070116] | Phase 2 | 300 participants (Anticipated) | Interventional | 2024-01-15 | Not yet recruiting | ||
| Microfilarial Clearance From the Eye and Ocular Changes Associated With Ivermectin Treatment in Individuals With Onchocerciasis[NCT03517462] | 231 participants (Actual) | Interventional | 2018-08-06 | Completed | |||
| [information is prepared from clinicaltrials.gov, extracted Sep-2024] | |||||||
The effectiveness of three treatment regimens for killing adult female O. volvulus worms based on the percentage of all adult female worms in nodules that are alive 18 months after treatment. (NCT04188301)
Timeframe: 18 months following treatment
| Intervention | Female worms in nodule (Count of Units) |
|---|---|
| IVM + ALB | 127 |
| IDA x 1 Dose | 142 |
| IDA x 3 Doses | 159 |
The effect of three treatment regimens for killing adult female O. volvulus worms will be compared based on the percentage of all adult female worms in nodules that are alive with embryos in the uterus 18 months after treatment. (NCT04188301)
Timeframe: 18 months following treatment.
| Intervention | Female worms in nodules (Count of Units) |
|---|---|
| IVM + ALB | 127 |
| IDA x 1 Dose | 142 |
| IDA x 3 Doses | 159 |
The effect of three treatment regimens for sterilizing adult female O. volvulus worms will be compared based on the percentage of all adult female worms that are fertile in the nodules 18 months after treatment. (NCT04188301)
Timeframe: 18 months following treatment.
| Intervention | Female worms with intact uterus (Count of Units) |
|---|---|
| IVM + ALB | 41 |
| IDA x 1 Dose | 40 |
| IDA x 3 Doses | 34 |
Rates of ocular adverse events of any grade within 3 months will be compared by treatment group. (NCT04188301)
Timeframe: within 3 months of treatment with IDA
| Intervention | Participants (Count of Participants) |
|---|---|
| IVM + ALB | 4 |
| IDA x 1 Dose | 4 |
| IDA x 3 Doses | 3 |
Rates of adverse events grade 3 or higher that occur within 7 days of treatment in the subset of participants who have intraocular microfilariae just prior to treatment with IDA will be compared by treatment group. (NCT04188301)
Timeframe: within 7 days following end of treatment
| Intervention | Participants (Count of Participants) |
|---|---|
| IVM + ALB | 0 |
| IDA x 1 Dose | 0 |
| IDA x 3 Doses | 0 |
Rates of severe adverse events (grade 3 or higher) following 1-day or 3-day triple drug treatment will be compared against those of the comparator regimen of 1 day of IVM/ALB. (NCT04188301)
Timeframe: Within 7 days following end of treatment
| Intervention | Participants (Count of Participants) |
|---|---|
| IVM + ALB | 0 |
| IDA x 1 Dose | 0 |
| IDA x 3 Doses | 0 |
The effectiveness of three treatment regimens for preventing reappearance of microfilariae in the skin as determined by skin snips at 12 and 18 months after treatment will be compared by treatment arm. Measured by the presence of microfilariae in skin snips. (NCT04188301)
Timeframe: Baseline, 12 months, and 18 months following treatment
| Intervention | Count of microfilarae+ participants (Number) | ||
|---|---|---|---|
| Baseline | Month 12 | Month 18 | |
| IDA x 1 Dose | 6 | 21 | 15 |
| IDA x 3 Doses | 0 | 21 | 17 |
| IVM + ALB | 7 | 23 | 20 |
The effectiveness of three treatment regimens for complete clearance of microfilariae from the skin as determined by skin snips at 3, 12, and 18 months after treatment with IDA will be compared by treatment arm. (NCT04188301)
Timeframe: Baseline, 3 months, 12 months, & 18 months following treatment.
| Intervention | Count of Skin Microfilaria (Geometric Mean) | |||
|---|---|---|---|---|
| Baseline | Month 3 | Month 12 | Month 18 | |
| IDA x 1 Dose | 1.7 | 3 | 2.5 | 9.0 |
| IDA x 3 Doses | NA | 2.1 | 4.7 | 8.6 |
| IVM + ALB | 3.1 | 1.9 | 4.9 | 7.0 |
2 trials available for diethylcarbamazine and Proteinuria
| Article | Year |
|---|---|
Proteinuria associated with diethylcarbamazine treatment of onchocerciasis.
Topics: Diethylcarbamazine; Humans; Onchocerciasis; Proteinuria | 1980 |
Ocular and systemic complications of diethylcarbamazine therapy for onchocerciasis: association with circulating immune complexes.
Topics: Antigen-Antibody Complex; Complement System Proteins; Diethylcarbamazine; Eye Diseases; Humans; Immu | 1983 |
Ocular and systemic complications of diethylcarbamazine therapy for onchocerciasis: association with circulating immune complexes.
Topics: Antigen-Antibody Complex; Complement System Proteins; Diethylcarbamazine; Eye Diseases; Humans; Immu | 1983 |
Ocular and systemic complications of diethylcarbamazine therapy for onchocerciasis: association with circulating immune complexes.
Topics: Antigen-Antibody Complex; Complement System Proteins; Diethylcarbamazine; Eye Diseases; Humans; Immu | 1983 |
Ocular and systemic complications of diethylcarbamazine therapy for onchocerciasis: association with circulating immune complexes.
Topics: Antigen-Antibody Complex; Complement System Proteins; Diethylcarbamazine; Eye Diseases; Humans; Immu | 1983 |
Ocular and systemic complications of diethylcarbamazine therapy for onchocerciasis: association with circulating immune complexes.
Topics: Antigen-Antibody Complex; Complement System Proteins; Diethylcarbamazine; Eye Diseases; Humans; Immu | 1983 |
Ocular and systemic complications of diethylcarbamazine therapy for onchocerciasis: association with circulating immune complexes.
Topics: Antigen-Antibody Complex; Complement System Proteins; Diethylcarbamazine; Eye Diseases; Humans; Immu | 1983 |
Ocular and systemic complications of diethylcarbamazine therapy for onchocerciasis: association with circulating immune complexes.
Topics: Antigen-Antibody Complex; Complement System Proteins; Diethylcarbamazine; Eye Diseases; Humans; Immu | 1983 |
Ocular and systemic complications of diethylcarbamazine therapy for onchocerciasis: association with circulating immune complexes.
Topics: Antigen-Antibody Complex; Complement System Proteins; Diethylcarbamazine; Eye Diseases; Humans; Immu | 1983 |
Ocular and systemic complications of diethylcarbamazine therapy for onchocerciasis: association with circulating immune complexes.
Topics: Antigen-Antibody Complex; Complement System Proteins; Diethylcarbamazine; Eye Diseases; Humans; Immu | 1983 |
4 other studies available for diethylcarbamazine and Proteinuria
| Article | Year |
|---|---|
Proteinuria associated with diethylcarbamazine.
Topics: Diethylcarbamazine; Humans; Onchocerciasis; Proteinuria | 1980 |
[Secondary effects of the treatment of hypermicrofilaremic loiasis using ivermectin].
Topics: Adult; Aged; Animals; Arthralgia; C-Reactive Protein; Cameroon; Diethylcarbamazine; Female; Fever; F | 1995 |
Renal disease in lymphatic filariasis: evidence for tubular and glomerular disorders at various stages of the infection.
Topics: Acetylglucosaminidase; Adolescent; Adult; Aged; Alpha-Globulins; Animals; Antibodies, Helminth; Brug | 1997 |
Renal abnormalities in microfilaremic patients with Bancroftian filariasis.
Topics: Adolescent; Adult; Animals; Blood Urea Nitrogen; Creatinine; Diethylcarbamazine; Elephantiasis, Fila | 1992 |